To evaluate the visual and auditory function in children and adolescents wh
o are undergoing monotherapy with sodium valproate, carbamazepine, and phen
obarbital visual-evoked potentials and brainstem auditory-evoked potentials
were measured in 58 epileptic patients (30 males and 28 females), ages 13.
7 +/- 6.9 years, Fifty healthy sex- and age-matched children served as cont
rols, The measurements were performed before the beginning of therapy and a
fter 12 months. Before the beginning of therapy, there were no significant
differences in visual- and auditory-evoked potentials between the control g
roup and the three groups of epileptic children. After 12 months of therapy
, patients treated with carbamazepine demonstrated a significant (P < 0.001
) increase of P100 latencies when compared with baseline data and control v
alues; moreover, these patients exhibited a significant increase of peak la
tencies of waves I-III-V and interpeak interval I-V at auditory second eval
uation. The patients treated with sodium valproate manifested a significant
(P < 0.05) increase in VEP P100 latencies. On the contrary, children recei
ving phenobarbital did not manifest any significant abnormality at visual-
and auditory-evoked potentials measurements. Our study demonstrates that fo
r patients treated with carbamazepine and sodium valproate, an electrophysi
ologic dysfunction of visual and auditory sensory pathways can be present a
fter 12 months of treatment. (C) 2000 by Elsevier Science Inc, All rights r
eserved.